Top Page
Moolec Science
(NASDAQ:MLEC)
Moolec Science (MLEC) vs. SPDR S&P 500 ETF (SPY)
Moolec Science Business Overview & Revenue Model
Moolec Science Financial Statement Overview
| Breakdown | TTM | Sep 2024 | Sep 2023 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.83M | 333.61M | 5.63M | 905.05K | 0.00 | 0.00 |
| Gross Profit | -639.50K | 114.01M | 472.58K | -143.31K | 0.00 | 0.00 |
| EBITDA | -5.21M | -69.01M | -6.16M | -51.74M | -3.65M | -13.80K |
| Net Income | -8.28M | -111.46M | -7.31M | -51.79M | -4.53M | -13.80K |
Balance Sheet | ||||||
| Total Assets | 31.38M | 204.71M | 34.79M | 24.05M | 5.69M | 138.59M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 9.02M | 5.39M | 2.83M | 1.08M | 337.60K |
| Total Debt | 22.09M | 246.88M | 14.68M | 2.65M | 125.00K | 125.00K |
| Total Liabilities | 28.58M | 287.58M | 27.97M | 13.95M | 4.09M | 4.51M |
| Stockholders Equity | 2.80M | -65.97M | 6.82M | 10.11M | 1.60M | 134.08M |
Cash Flow | ||||||
| Free Cash Flow | -6.12M | -30.10M | -9.49M | -7.69M | -1.89M | -8.80K |
| Operating Cash Flow | -5.70M | -24.45M | -9.33M | -7.51M | -1.89M | -8.80K |
| Investing Cash Flow | -270.17K | -35.99M | 134.87K | -2.34M | -138.00M | 0.00 |
| Financing Cash Flow | 5.95M | 13.07M | 11.71M | 11.28M | 139.05M | 14.49K |
Moolec Science Technical Analysis
Moolec Science Risk Analysis
Moolec Science Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $11.41M | -0.50 | -174.68% | ― | 170.36% | -24.98% | |
47 Neutral | $5.18M | -1.71 | -24.80% | ― | 1371.65% | 64.13% | |
45 Neutral | $5.45M | -0.09 | ― | ― | ― | 87.42% | |
43 Neutral | $1.42M | -0.06 | -270.54% | ― | 1.51% | 77.64% | |
40 Underperform | $4.26M | -0.05 | ― | ― | -41.05% | 57.35% |
Moolec Science Corporate Events
On February 25, 2025, Moolec Science SA, a plant- and microbe-based protein innovator for the global food industry, announced a reshaping of its board of directors. The company appointed U.S.-based quality and operations veteran Daniel Core to its board, adding him to both the audit and compensation committees to bolster governance, compliance oversight, and operational risk management.
Effective the same day, directors Aimar Dimo and Gloria Montaron Estrada resigned from the board, marking a notable refresh of Moolec’s governance structure. The changes signal an increased emphasis on industrial-quality discipline and regulatory frameworks as the company advances its technology-driven, seed-to-ingredient strategy across its key markets in the United States, Europe, and South America.
The most recent analyst rating on (MLEC) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
On January 30, 2026, Moolec Science announced that a Nasdaq Hearings Panel has granted the company continued listing on the Nasdaq Stock Market, after Moolec regained compliance with the minimum bid price requirement on January 16, 2026, following a reverse stock split that became effective on January 5, 2026, and filed its delayed annual report for the fiscal year ended June 30, 2025 on December 29, 2025. The panel’s decision keeps Moolec under Nasdaq oversight through May 13, 2026 and is contingent on the company meeting several conditions, including providing updates on derecognition proceedings by the end of February 2026, submitting updated pro forma financial information by the end of March 2026, publicly disclosing actions taken to meet equity and listing standards by May 13, 2026, and proving full compliance with all Nasdaq Capital Market continued listing requirements by that date, a framework that underscores both the company’s precarious past compliance status and the critical importance for shareholders of Moolec successfully executing its financial and strategic plans to preserve its U.S. listing.
The most recent analyst rating on (MLEC) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
On January 22, 2026, Moolec Science S.A. announced that a Nasdaq Hearings Panel has granted the company an exception until June 29, 2026 to demonstrate compliance with Nasdaq’s minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), subject to certain disclosure conditions. The company’s equity position improved after bankruptcy filings by several subsidiaries at the end of December 2025 triggered derecognition events under IFRS 10, allowing Moolec to recognize estimated gains of about $91.0 million from loss of control of Bioceres S.A., $5.2 million from Bioceres LLC, and $4.6 million from Theo I SCSp, alongside the recognition of previously eliminated intercompany balances and the conversion of certain preference shares into ordinary shares; Moolec believes these changes have already brought it back into compliance with Nasdaq’s equity standards and has notified the exchange as it continues working to maintain its listing.
The most recent analyst rating on (MLEC) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
On January 5, 2026, Moolec Science SA implemented a 15-for-1 consolidation of its ordinary shares, following shareholder approval at an extraordinary general meeting on December 16, 2025 and subsequent board resolutions on December 19, 2025. The transaction, effective at 8:00 a.m. Eastern Time and reflected in trading the same day, reduced the number of issued and outstanding ordinary shares from 10,891,761 to 726,118 while increasing par value per share from US$0.10 to US$1.50, without requiring any action from shareholders. Moolec’s ordinary shares continue to trade on Nasdaq under the ticker “MLEC” with a new CUSIP, and its warrants under “MLECW” with an unchanged CUSIP; the company emphasized that the consolidation does not affect its business or operations, but materially alters the capital structure and share count for existing investors.
The most recent analyst rating on (MLEC) stock is a Hold with a $0.27 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
On December 30, 2025, Moolec Science SA received an additional determination letter from Nasdaq’s Listing Qualifications Department stating that the company no longer meets the minimum stockholders’ equity requirement of $2.5 million under Listing Rule 5550(b)(1). As previously disclosed in its Form 20-F for the year ended June 30, 2025, Moolec’s management expects to regain compliance with Nasdaq’s continued listing standards through recognition of an estimated $105.8 million gain from the derecognition of certain subsidiaries that entered bankruptcy, a process that is already underway. The company anticipates that this accounting gain will result in positive net income sufficient to satisfy Nasdaq’s $500,000 net income standard, and it made this disclosure in line with Nasdaq’s requirement for prompt public notice after a non-compliance notification, signaling an important phase in Moolec’s efforts to secure its continued listing and reassure investors about its regulatory standing.
The most recent analyst rating on (MLEC) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
On December 31, 2025, Moolec Science SA announced that its board of directors has set January 5, 2026, as the effective date for a 15‑for‑1 consolidation of its ordinary shares, reducing the number of issued and outstanding shares from 10,891,761 to approximately 726,118, with any fractional entitlements rounded up to the nearest whole share. The consolidated shares, which will carry a new par value of US$1.50 and trade under a new CUSIP on the Nasdaq Capital Market, are intended to help the company regain compliance with Nasdaq’s minimum US$1.00 bid price requirement, a move that could stabilize its listing status and is therefore significant for shareholders and other market stakeholders.
The most recent analyst rating on (MLEC) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
On December 16, 2025, Moolec Science SA held a virtual extraordinary general meeting of shareholders where two key resolutions were approved. The first resolution involved a share consolidation at a ratio of 1-for-10 to 1-for-25, effective between December 17, 2025, and May 14, 2026. The second resolution approved the adoption of amended and restated memorandum and articles of association to reflect the share consolidation. These changes are expected to impact the company’s share structure and governance.
The most recent analyst rating on (MLEC) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
Moolec Science SA announced the adjournment of its extraordinary general meeting of shareholders to December 16, 2025, due to the lack of a quorum, as only 39.846% of the shares were voted. The adjourned meeting will proceed with any number of shareholders present, allowing them to deliberate and resolve the matters intended for the original meeting, impacting the company’s governance and decision-making processes.
The most recent analyst rating on (MLEC) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
On November 24, 2025, Moolec Science received a notification from Nasdaq indicating non-compliance with the requirement to file its Annual Report on Form 20-F for the year ended June 30, 2025. This delay stems from complexities following a business combination in mid-June 2025, involving intricate accounting and valuation processes. Moolec has requested a stay of suspension, allowing its shares to continue trading on Nasdaq until a hearing scheduled for December 18, 2025. The company is actively working to complete the filing before the hearing, aiming to maintain its Nasdaq listing.
The most recent analyst rating on (MLEC) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.